Microbot Medical Inc. Files 8-K Report

TL;DR

Microbot Medical filed an 8-K on Feb 10, 2025. Standard update.

AI Summary

Microbot Medical Inc. filed an 8-K report on February 10, 2025, to disclose other events and financial statements. The company, incorporated in Delaware, is involved in the surgical and medical instruments sector. Its principal executive offices are located in Braintree, MA.

Why It Matters

This filing provides an update on Microbot Medical Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for disclosure purposes and does not appear to contain significant new risks.

Key Numbers

• 000-19871 — Commission File Number (Identifies the company's filing with the SEC.)
• 94-3078125 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Microbot Medical Inc. (company) — Registrant
• February 10, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Braintree, MA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value MBOT NASDAQ Capital Mark
• $1.75 — ur common stock at an offering price of $1.75 per share. In a concurrent private plac
• $7.0 million — ry 7, 2025, and we raised approximately $7.0 million in aggregate gross proceeds from such o
• $2.1875 — issuance, and have an exercise price of $2.1875 per share. On January 7, 2025, we ent
• $2.27 — ur common stock at an offering price of $2.27 per share. In a concurrent private plac
• $2.10 — ur common stock at an exercise price of $2.10 per share. Each series H preferred inve
• $8.6 million — y 10, 2025, and we raised approximately $8.6 million in aggregate gross proceeds from such o
• $2.8375 — issuance, and have an exercise price of $2.8375 per share. ATM Offering On June 10,
• $4,819,905 — ng an aggregate offering price of up to $4,819,905 at market prices or as otherwise agreed
• $4,819,278 b — Agreement, for total gross proceeds of $4,819,278 before deducting aggregate placement fees
• $144,578 — e deducting aggregate placement fees of $144,578 and other offering expenses. Accordingl
• $3.6 m — a net working capital of approximately $3.6 million, consisting primarily of cash and
• $4.1 million — to net working capital of approximately $4.1 million as of December 31, 2023. This does not
• $20.6 million — e into account any of the approximately $20.6 million we raised subsequent to September 30, 2
• $93.4 million — s raised cash proceeds of approximately $93.4 million. Since inception (November 2010) throug

Filing Documents

• form8-k.htm (8-K) — 236KB
• 0001493152-25-005489.txt ( ) — 430KB
• mbot-20250210.xsd (EX-101.SCH) — 3KB
• mbot-20250210_lab.xml (EX-101.LAB) — 33KB
• mbot-20250210_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 000-19871 94-3078125 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 288 Grove Street , Suite 388 Braintree , MA 02184 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (781) 875-3605 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value MBOT NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. Overview Microbot Medical Inc. (the "Company", "we" or "us") is a clinical-stage medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. We are primarily focused on leveraging our robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. Using our LIBERTY technological platform, we are developing the first ever fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body's vasculature. It is intended for the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters to facilitate navigation to anatomical targets in the peripheral vasculature. It is designed to eliminate the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Recent Developments Registered Direct Offerings and Concurrent Private Placements On January 6, 2025, we entered into a securities purchase agreement with investors, pursuant to which we agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market, an aggregate of 4,000,001 shares of our common stock at an offering price of $1.75 per share. In a concurrent private placement, we agreed to issue to the same investors series G preferred investment options to purchase up to 8,000,002 shares of our common stock at an exercise price of $1.75 per share. Each series G preferred investment option was exercisable immediately and expires two years from the initial exercise date. The offerings closed on January 7, 2025, and we raised approximately $7.0 million in aggregate gross proceeds from such offerings, before deducting placement agent fees and expenses and related offering expenses. We also issued at closing to the placement agent or its designees, warrants to purchase 200,000 shares of our common stock, which were exercisable immediately, expire two years from issuance, and have an exercise price of $2.1875 per share. On January 7, 2025, we entered into a securities purchase agreement with investors, pursuant to which we agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market, an aggregate of 3,788,550 shares of our common stock at an offering price of $2.27 per share. In a concurrent private placement, we agreed to issue to the same investors series H preferred investment options to purchase up to 7,577,100 shares of our common stock at an exercise price of $2.10 per share. Each series H preferred investment option was exercisable immediately and expires two years from the initial exercise date. The offerings closed on January 10, 2025, and we ra

View Full Filing

View this 8-K filing on SEC EDGAR